OCGN · Ocugen, Inc.

0001104659-26-061241

Summary

Ocugen, Inc. announced the separation of Chief Medical Officer Huma Qamar, M.D., MPH, CMI, effective May 8, 2026, and appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer on the same date.

Key takeaways

Huma Qamar, M.D., MPH, CMI separated from Ocugen, Inc. as Chief Medical Officer effective May 8, 2026.
Mohamed Genead, M.D., M.Sc. appointed as Acting/Interim Chief Medical Officer effective May 8, 2026.
Leadership transition in critical medical role for clinical development oversight.
No compensation details or reasons for departure disclosed.

Full analysis

The departure of Huma Qamar as Chief Medical Officer and immediate appointment of Mohamed Genead as Acting/Interim Chief Medical Officer signals a swift leadership transition in Ocugen's medical function. This role is pivotal for overseeing clinical trials and regulatory interactions in a biotech context. The lack of disclosed reasons for the separation or details on Genead's compensation leaves the full context unclear, but the back-to-back timing minimizes operational disruption.